Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Chemo-brain: early-phase trial registry

3 of 5 indexed Chemo-brain trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Chemo-brain: 5 US clinical trials tracked, 3 recruiting.

Chemo-brain is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Joseph McCollom, running 1 of these trials.

Enrollment posture brief

Registry condition chemo-brain

OPEN 3 | RECR 60% | LATE 0 | EARLY 1 | RANK #3391 | SPON 1

Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Chemo-brain (this)60%
Open-enrollment share among volume-matched conditions near Chemo-brain

Chemo-brain lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chemo-brain on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Chemo-brain is recruiting above its size-band peers.

    3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Chemo-brain research.

    Joseph McCollom accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Chemo-brain trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Chemo-brain research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Chemo-brain records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Transdermal Patch Other
1 trials
Transdermal nicotine Drug
1 trials
Active Control Condition Behavioral
1 trials
Neuroplasticity-based Computerized Cognitive Remediation Behavioral
1 trials
PET Scan Radiation
1 trials
Cognitive, functional and subjective assessments Other
1 trials
Cognitive training application Device
1 trials
MRI Device
1 trials

US sites by state

Facility locations filed on Chemo-brain trials. A trial with sites in several states counts in each.

Massachusetts 2 trials
Tennessee 1 trials
Indiana 1 trials
Alabama 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Chemo-brain page

5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chemo-brain condition card totals 5 registered trials; most-linked intervention Placebo Transdermal Patch; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.